Thakur Jitender, Rathi Sahaj, Grover Sandeep, Chopra Madhu, Agrawal Swastik, Taneja Sunil, Duseja Ajay, Bhansali Anil, Chawla Yogesh K, Dhiman Radha K
Department of Hepatology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
J Clin Exp Hepatol. 2019 May-Jun;9(3):312-317. doi: 10.1016/j.jceh.2018.07.007. Epub 2018 Aug 18.
Erectile dysfunction(ED) is common in patients with chronic liver disease(CLD). Although it significantly worsens the quality of life, caregivers and researchers often neglect it.
Evaluating the prevalence of ED in patients with CLD, associated factors, and response to therapy with tadalafil, a phosphodiesterase-5 inhibitor.
A total of 60 males with Child-Pugh score between 5 and 10 and no overt hepatic encephalopathy were studied. ED was assessed based on the 15-question International Index of Erectile Function (IIEF) questionnaire. Patients were classified as ED+ if score was <25. Patients with ED were given 10 mg of tadalafil for 4 weeks.
The mean age was 45.2 he 7.8 years. The mean Child-Turcotte-Pugh (CTP) score was 6.4 sc 1.7, and model for end-stage liver disease (MELD) score was 12.1 sc 4.5. Twenty-seven (45%) patients had compensated cirrhosis, and 45(75%) had alcohol as etiology. Twenty-five (42%) had an IIEF score <25, suggestive of ED. The IIEF score had significant correlation with the presence of ascites(r = -0.27, 0.04) and serum creatinine (r -0.26, = 0.05); however, there was no correlation with CTP, MELD, or alcohol as etiology. Among ED group, IIEF scores improved significantly with 4 weeks of tadalafil therapy (15.1 ± 5.6 vs 22.0 ± 3.4, < 0.001), and 11(44%) had resolution of ED.
ED is common in patients with cirrhosis. Tadalafil administration significantly improves ED in these patients.
勃起功能障碍（ED）在慢性肝病（CLD）患者中很常见。尽管它会显著降低生活质量，但护理人员和研究人员常常忽视它。
评估CLD患者中ED的患病率、相关因素以及对磷酸二酯酶-5抑制剂他达拉非治疗的反应。
共研究了60名Child-Pugh评分为5至10且无明显肝性脑病的男性。根据15个问题的国际勃起功能指数（IIEF）问卷评估ED。如果得分<25，则患者被分类为ED+。ED患者给予10毫克他达拉非治疗4周。
平均年龄为45.2±7.8岁。平均Child-Turcotte-Pugh（CTP）评分为6.4±1.7，终末期肝病模型（MELD）评分为12.1±4.5。27名（45%）患者患有代偿期肝硬化，45名（75%）患者的病因是酒精。25名（42%）患者的IIEF得分<25，提示存在ED。IIEF得分与腹水的存在（r = -0.27，P = 0.04）和血清肌酐（r = -0.26，P = 0.05）显著相关；然而，与CTP、MELD或病因是酒精无关。在ED组中，他达拉非治疗4周后IIEF得分显著改善（15.1±5.
